COLL

Kuhlmann Shirley R.

Known title: EVP and General CounselCIK: 0001734919

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.

this person other insiders at COLL

Transaction History

COLL▼ Sell$743K
COLL▼ Sell$561K
COLL▲ Buy$961K
COLL▼ Sell$1.1M
COLL▼ Sell$300K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▼ Sell$768K
COLL▲ Buy$587K
COLL▼ Sell$703K
COLL▼ Sell$205K
COLL▼ Sell$37K
COLL▼ Sell$643K
COLL▼ Sell$94K
COLL▼ Sell$23K
COLL▼ Sell$791K
COLL▼ Sell$713K
COLL▼ Sell$358K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▲ Buy$407K
COLL▼ Sell$660K
COLL▼ Sell$360K
COLL▼ Sell$31K
COLL▼ Sell$586K
COLL▼ Sell$436K
COLL▼ Sell$207K
COLL▲ Buy—
COLL▲ Buy$0
COLL▼ Sell$697K
COLL▼ Sell$6K
COLL▼ Sell$14K
COLL▼ Sell$123K
COLL▼ Sell$74K
COLL▲ Buy$0
COLL▲ Buy—
COLL▼ Sell$14K

We use analytics to understand how market-wall is used. No personal data is sold.